Effect of bone marrow mesenchymal stem cells transplantation on the expression of CD163 and interleukin-10 in rats with acute hepatic liver failure

doi:10.3969/j.issn.2095-4344.2014.06.016

Abstract

Abstract:

BACKGROUND: Studies have shown that bone marrow mesenchymal stem cells have the ability to persistently generate hepatocytes and biliary cells, and thus in the repair process of liver injury, replenish the reduced number of hepatocytes due to damage and participate in damaged liver structure.

OBJECTIVE: To investigate the effect of bone marrow mesenchymal stem cells transplantation on acute liver failure and the expression of CD163 and interleukin-10 in rat serum and liver tissue.

METHODS: D-galactose and lipopolysaccharidewere used to make acute liver failure models in 60 Sprague-Dawley rats. Then, the rats were divided into control group and transplantation group. Bone marrow mesenchymal stem cells at passage 3 were injected through tail vein in the transplantation group, and normal saline was injected in the control group. After transplantation 24, 120, 168 hours, serum samples and liver tissues were collected.

RESULTS AND CONCLUSION: After transplantation 120 and 168 hours, the serum alanine transaminase and aspartate aminotransferase activities of the transplantation were significantly lower than those of the control group (P < 0.05). In the transplantation group the apoptotic index was still lower compared with the control group, and the difference was significant (P < 0.05). The levels of CD163 and interleukin-10 in the serum and liver tissue in the transplantation group were decreased significantly compared with the control group (P < 0.05). The results suggested that there were highly significant correlations between CD163 and interleukin-10 (P < 0.01). Bone marrow mesenchymal stem cell transplantation has a therapeutic effect on acute liver failure rats. CDl63 and interleukin-10 play a very important role in the pathogenesis of acute liver failure, which can be used as sensitive serum marker proteins for diagnosis and prognosis of acute liver failure.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: bone marrow, mesenchymal stem cells, rats, Sprague-Dawley, liver fracture, acute, interleukin-10

CLC Number:

R394.2

Yuan Shu-fang, Hu Lan-ying, Jiang Tao, Sun Li-hua, Zheng Rong-jiong, Zhao Jin-yan, Zhang Yue-xin . Effect of bone marrow mesenchymal stem cells transplantation on the expression of CD163 and interleukin-10 in rats with acute hepatic liver failure[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(6): 919-925.

Figures/Tables 3

References

[1] Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev. 2010;90(3):1165- 1194.

[2] Kharaziha P, Hellström PM, Noorinayer B,et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial.Eur J Gastroenterol Hepatol. 2009;21(10):1199-1205.

[3] Li J, Zhang L, Xin J,et al. Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs. Hepatology. 2012;56(3):1044-1052.

[4] Chen Y, Xiang LX, Shao JZ,et al. Recruitment of endogenous bone marrow mesenchymal stem cells towards injured liver.J Cell Mol Med. 2010;14(6B):1494-1508.

[5] Amer ME, El-Sayed SZ, El-Kheir WA,et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells.Eur J Gastroenterol Hepatol. 2011;23(10):936-941.

[6] Peng L, Xie DY, Lin BL,et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54(3):820-828.

[7] Fan CG, Zhang QJ, Zhou JR.Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord.Stem Cell Rev. 2011;7(1):195-207.

[8] Shi M, Zhang Z, Xu R,et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients.Stem Cells Transl Med. 2012;1(10):725-731.

[9] Zagoura DS, Roubelakis MG, Bitsika V,et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure.Gut. 2012;61(6):894-906.

[10] Herrera MB, Fonsato V, Bruno S,et al. Human liver stem cells improve liver injury in a model of fulminant liver failure. Hepatology. 2013;57(1):311-319.

[11] Kuo TK, Hung SP, Chuang CH,et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008; 134(7):2111-2121.

[12] Kumar R, Shalimar, Sharma H,et al. Prospective derivation and validation of early dynamic model for predicting outcome in patients with acute liver failure. Gut. 2012;61(7): 1068-1075.

[13] Stuart WD, Kulkarni RM, Gray JK,et al. Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice. Hepatology. 2011;53(5):1618-1628.

[14] Bassi ÊJ, de Almeida DC, Moraes-Vieira PM,et al. Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells.Stem Cell Rev. 2012; 8(2):329-342.

[15] Zhang Z, Lin H, Shi M,et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients.J Gastroenterol Hepatol. 2012;27 Suppl 2:112-120.

[16] Wlodzimirow KA, Eslami S, Abu-Hanna A,et al. Systematic review: acute liver failure - one disease, more than 40 definitions. Aliment Pharmacol Ther. 2012;35(11):1245- 1256.

[17] Davis BH, Zarev PV. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom. 2005;63(1):16-22.

[18] Hiraoka A, Horiike N, Akbar SM,et al. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.J Gastroenterol. 2005; 40(1):52-56.

[19] Maniecki MB, Møller HJ, Moestrup SK,et al. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes.Immunobiology. 2006;211(6-8): 407-417.

[20] Pietrosi G, Vizzini GB, Gruttadauria S,et al. Clinical applications of hepatocyte transplantation.World J Gastroenterol. 2009;15(17):2074-2077.

[21] Berry PA, Antoniades CG, Hussain MJ,et al. Admission levels and early changes in serum interleukin-10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis.Liver Int. 2010;30(5):733-740.

[22] Bourdi M, Eiras DP, Holt MP,et al. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury.Chem Res Toxicol. 2007; 20(2):208-216.

[23] Weaver LK, Hintz-Goldstein KA, Pioli PA,et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163.J Leukoc Biol. 2006;80(1):26-35.

[24] 谷甸娜, 陈永平, 卢明芹, 等. CD163和血红素加氧酶1在急性肝衰竭大鼠模型中的表达[J].中华肝脏病杂志, 2008, 16(12): 944-945.

[25] Salama H, Zekri AR, Zern M,et al. Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases.Cell Transplant. 2010;19(11):1475-1486.

[26] Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008; 9(3):231-241.

[27] Bernal W, Auzinger G, Dhawan A,et al. Acute liver failure. Lancet. 2010;376(9736):190-201.

[28] Li TZ, Kim JH, Cho HH,et al.Therapeutic potential of bone-marrow-derived mesenchymal stem cells differentiated with growth-factor-free coculture method in liver-injured rats.Tissue Eng Part A. 2010;16(8):2649-2659.

[29] 史贵秀, 孙丽华, 张跃新. 5-乙炔基-2’脱氧尿嘧啶核苷标记大鼠骨髓间充质干细胞的有效性[J]. 中国组织工程研究, 2012, 16(1): 17-21.

[30] Deuse T, Stubbendorff M, Tang-Quan K,et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells.Cell Transplant. 2011;20(5): 655-667.

[31] Kim JK, Park YN, Kim JS,et al. Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis.Cell Transplant. 2010;19(10): 1237-1246.

[32] Soltys KA, Soto-Gutiérrez A, Nagaya M,et al. Barriers to the successful treatment of liver disease by hepatocyte transplantation. J Hepatol. 2010;53(4):769-774.

[33] Dhawan A, Puppi J, Hughes RD,et al. Human hepatocyte transplantation: current experience and future challenges.Nat Rev Gastroenterol Hepatol. 2010;7(5):288-298.

[34] Peng L, Xie DY, Lin BL,et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54(3):820-828.

[35] Muraca M. Evolving concepts in cell therapy of liver disease and current clinical perspectives. Dig Liver Dis. 2011;43(3): 180-187.

[36] Parekkadan B, van Poll D, Suganuma K,et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One. 2007;2(9):e941.

[37] 刘迎娣,杨云生,王韫芳,等.经脾脏hMSCs移植对乙酰氨基酚所致小鼠急性肝损伤的治疗作用[J].世界华人消化杂志, 2008, 16(18): 1969-1973.

[38] 郭晓钟,王迪,邵晓冬,等.自体骨髓干细胞移植治疗失代偿期肝硬化[J].中华消化杂志,2009,29(7):433-436.

[39] Hiraoka A, Horiike N, Akbar SM,et al. Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract. 2005; 201(5):379-384.

[40] Schaer DJ, Schaer CA, Schoedon G,et al. Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur J Haematol. 2006; 77(5):432-436.

[41] Fabriek BO, van Bruggen R, Deng DM,et al. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood. 2009;113(4):887-892.

[42] Van Gorp H, Delputte PL, Nauwynck HJ.Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy.Mol Immunol. 2010;47(7-8):1650-1660.

[43] Møller HJ, Nielsen MJ, Maniecki MB,et al. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding. Immunobiology. 2010;215(5):406-412.

[44] Møller HJ, Grønbaek H, Schiødt FV,et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. Hepatol. 2007;47(5):671-676.

[45] Philippidis P, Mason JC, Evans BJ,et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 2004;94(1):119-126.

[46] Moreno JA, Muñoz-García B, Martín-Ventura JL,et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009;207(1):103-110.

[47] 李珊珊,陈煜,段钟平.CD163与sCD163:肝衰竭评价的新指标[J].临床肝胆病杂志, 2011, 27(10):1112-1115．

[48] Møller HJ, Frikke-Schmidt R, Moestrup SK,et al. Serum soluble CD163 predicts risk of type 2 diabetes in the general population.Clin Chem. 2011;57(2):291-297.

[49] 谷甸娜,陈永平,张晓华,等.乌司他丁对急性肝功能衰竭大鼠肝组织中血红素加氧酶-1 mRNA和蛋白表达的影响[J].中华传染病杂志, 2009, 27(4): 207-211.

[50] 吴会玲.慢加急性肝衰竭内毒素血症对清道夫受体CD163作用的研究[D].武汉:华中科技大学, 2010: 58-59.